Takeda, Merck Diabetes Drug Combo Shown To Lower Blood Sugar
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical's Actos (pioglitazone) and Merck's Januvia (sitagliptin) have shown in a study to be effective when used with insulin therapy to lower blood sugar in type 2 diabetics. Data from two clinical trials on lowering blood sugar showed a 2.4 percent reduction in a key measure of average blood glucose level over a two- to three-month period. The lowering of A1C levels from 8 percent to 12 percent to a relatively safe level of 7 percent or less was considered statistically significant. The trials combined Merck's new-generation drug with Takeda's older class of drug. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.